Pharmaceuticals & Biotechnology
Valuation | |
|---|---|
| Market Cap | 15.45 kCr |
| Price/Earnings (Trailing) | 32.16 |
| Price/Sales (Trailing) | 2.02 |
| EV/EBITDA | 13.63 |
| Price/Free Cashflow | -392.89 |
| MarketCap/EBT | 22.66 |
| Enterprise Value | 17.42 kCr |
Fundamentals | |
|---|---|
Growth & Returns | |
|---|---|
| Price Change 1W | 0.80% |
| Price Change 1M | -9.4% |
| Price Change 6M | -11.8% |
| Price Change 1Y | 1.4% |
| 3Y Cumulative Return | 41.3% |
| 5Y Cumulative Return | 1.2% |
| 7Y Cumulative Return | 4.3% |
| 10Y Cumulative Return | 10.8% |
| Revenue (TTM) |
| 7.66 kCr |
| Rev. Growth (Yr) | 11.4% |
| Earnings (TTM) | 474.4 Cr |
| Earnings Growth (Yr) | 17% |
Profitability | |
|---|---|
| Operating Margin | 9% |
| EBT Margin | 9% |
| Return on Equity | 7.22% |
| Return on Assets | 3.51% |
| Free Cashflow Yield | -0.25% |
Cash Flow & Liquidity |
|---|
| Cash Flow from Investing (TTM) | 487.7 Cr |
| Cash Flow from Operations (TTM) | 1.07 kCr |
| Cash Flow from Financing (TTM) | -1.45 kCr |
| Cash & Equivalents | 622.7 Cr |
| Free Cash Flow (TTM) | -43.5 Cr |
| Free Cash Flow/Share (TTM) | -2.73 |
Balance Sheet | |
|---|---|
| Total Assets | 13.52 kCr |
| Total Liabilities | 6.95 kCr |
| Shareholder Equity | 6.57 kCr |
| Current Assets | 3.4 kCr |
| Current Liabilities | 2.09 kCr |
| Net PPE | 3.24 kCr |
| Inventory | 1.23 kCr |
| Goodwill | 2.65 kCr |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.19 |
| Debt/Equity | 0.4 |
| Interest Coverage | 2.29 |
| Interest/Cashflow Ops | 5.91 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 5 |
| Dividend Yield | 0.52% |
| Shares Dilution (1Y) | 0.00% |
| Shares Dilution (3Y) | 0.00% |
Smart Money: Smart money has been increasing their position in the stock.
Balance Sheet: Strong Balance Sheet.
Size: Market Cap wise it is among the top 20% companies of india.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Past Returns: Outperforming stock! In past three years, the stock has provided 41.3% return compared to 13% by NIFTY 50.
Technicals: Bullish SharesGuru indicator.
Momentum: Stock has a weak negative price momentum.
Smart Money: Smart money has been increasing their position in the stock.
Balance Sheet: Strong Balance Sheet.
Size: Market Cap wise it is among the top 20% companies of india.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Past Returns: Outperforming stock! In past three years, the stock has provided 41.3% return compared to 13% by NIFTY 50.
Technicals: Bullish SharesGuru indicator.
Momentum: Stock has a weak negative price momentum.
Investor Care | |
|---|---|
| Dividend Yield | 0.52% |
| Dividend/Share (TTM) | 5 |
| Shares Dilution (1Y) | 0.00% |
| Earnings/Share (TTM) | 30.16 |
Financial Health | |
|---|---|
| Current Ratio | 1.63 |
| Debt/Equity | 0.4 |
Technical Indicators | |
|---|---|
| RSI (14d) | 35.61 |
| RSI (5d) | 52.69 |
| RSI (21d) | 37.65 |
| MACD Signal | Buy |
| Stochastic Oscillator Signal | Hold |
| SharesGuru Signal | Buy |
| RSI Signal | Hold |
| RSI5 Signal | Hold |
| RSI21 Signal | Hold |
| SMA 5 Signal | Buy |
| SMA 10 Signal |
Summary of JUBILANT PHARMOVA's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
Understand JUBILANT PHARMOVA ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| SPB TRUSTEE COMPANY PVT LTD | 20.08% |
| HSB TRUSTEE COMPANY PVT LTD | 19% |
| REKHA JHUNJHUNWALA | 3.28% |
| MILLER HOLDINGS PTE LTD | 3.28% |
| MAV MANAGEMENT ADVISORS LLP | 3.15% |
| GOVERNMENT PENSION FUND GLOBAL | 3.14% |
| EAST BRIDGE CAPITAL MASTER FUND I LTD | 2.53% |
Detailed comparison of JUBILANT PHARMOVA against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries | 3.83 LCr | 58.94 kCr | -1.40% | -3.40% | 35.06 | 6.49 | - | - |
| DIVISLAB | Divi's Lab | 1.61 LCr |
Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distribution, sale, and marketing of generic formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment offers drug discovery and development services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment provides patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. It serves pharmaceutical, biotech, group purchasing organisations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is based in Noida, India.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
| Buy |
| SMA 20 Signal | Sell |
| SMA 50 Signal | Sell |
| SMA 100 Signal | Sell |
| KOTAK MAHINDRA TRUSTEE CO LTD A/C KOTAK MULTICAP FUND | 2.44% |
| THELEME INDIA MASTER FUND LIMITED | 1.66% |
| Investor Education and Protection Fund Authority Ministry of Corporate Affairs | 1.28% |
| ABAKKUS EMERGING OPPORTUNITIES FUND-1 | 1.15% |
| NIKITA RESOURCES PRIVATE LIMITED | 0.97% |
| PRIYAVRAT BHARTIA | 0.88% |
| HARI SHANKER BHARTIA | 0.23% |
| SHAMIT BHARTIA | 0.08% |
| KAVITA BHARTIA | 0.01% |
| TORINO OVERSEAS LIMITED | 0% |
| CUMIN INVESTMENTS LIMITED | 0% |
| RANCE INVESTMENT HOLDINGS LIMITED | 0% |
| JUBILANT ENPRO PRIVATE LIMITED | 0% |
Distribution across major stakeholders
Distribution across major institutional holders
| 10.46 kCr |
| -4.90% |
| -0.70% |
| 64.69 |
| 15.36 |
| - |
| - |
| CIPLA | Cipla | 1.07 LCr | 29.37 kCr | -12.60% | -8.30% | 23.61 | 3.65 | - | - |
| DRREDDY | Dr. Reddy's Lab | 1.04 LCr | 36.09 kCr | -0.80% | +1.70% | 18.55 | 2.87 | - | - |
| AUROPHARMA | Aurobindo Pharma | 70.43 kCr | 33.03 kCr | +0.40% | +3.50% | 20.58 | 2.13 | - | - |
| 1,780 |
| 1,758 |
| 1,731 |
| 1,681 |
| 1,615 |
| 1,642 |
| Profit Before exceptional items and Tax | 27.5% | 196 | 154 | 209 | 150 | 159 | 104 |
| Exceptional items before tax | - | -5.8 | 0 | -3.3 | -18.9 | -14.2 | 396 |
| Total profit before tax | 23.5% | 190 | 154 | 206 | 131 | 144 | 500 |
| Current tax | -5.4% | 36 | 38 | 115 | 32 | 40 | 26 |
| Deferred tax | 153.8% | 34 | 14 | -60.1 | -2.5 | 1.9 | -8.2 |
| Total tax | 35.3% | 70 | 52 | 55 | 30 | 42 | 18 |
| Total profit (loss) for period | 17.8% | 120 | 102 | 151 | 101 | 102 | 482 |
| Other comp. income net of taxes | 297.5% | 160 | 41 | -4.6 | 64 | 30 | -3.9 |
| Total Comprehensive Income | 95.1% | 280 | 144 | 147 | 164 | 132 | 478 |
| Earnings Per Share, Basic | 20% | 7.59 | 6.49 | 9.71 | 6.37 | 6.47 | 30.44 |
| Earnings Per Share, Diluted | 20.1% | 7.57 | 6.47 | 9.68 | 6.36 | 6.46 | 30.35 |
| 6.9% |
| 203 |
| 190 |
| 167 |
| 49 |
| 221 |
| 265 |
| Finance costs | 0% | 30 | 30 | 19 | 31 | 102 | 136 |
| Depreciation and Amortization | 10.6% | 53 | 48 | 43 | 6.25 | 100 | 107 |
| Other expenses | 5.4% | 235 | 223 | 225 | 45 | 611 | 820 |
| Total Expenses | -5.9% | 796 | 846 | 869 | 131 | 2,484 | 3,013 |
| Profit Before exceptional items and Tax | 17.1% | 49 | 42 | 79 | 82 | 273 | 301 |
| Exceptional items before tax | - | -11.2 | 0 | 0 | 0 | 0 | -1.7 |
| Total profit before tax | -9.8% | 38 | 42 | 79 | 82 | 273 | 299 |
| Current tax | 227.6% | 20 | 6.8 | 14 | 14 | 45 | 26 |
| Deferred tax | -204.3% | -1.4 | 3.3 | 16 | -9.91 | 13 | -48.43 |
| Total tax | 88.9% | 18 | 10 | 29 | 3.75 | 59 | -22.3 |
| Total profit (loss) for period | -41.9% | 19 | 32 | 50 | 78 | 214 | 321 |
| Other comp. income net of taxes | 13.3% | -0.3 | -0.5 | 1.32 | 0.02 | -1.75 | -1.88 |
| Total Comprehensive Income | -40% | 19 | 31 | 51 | 79 | 213 | 319 |
| Earnings Per Share, Basic | -78.8% | 1.21 | 1.99 | 3.13 | 4.93 | 13.47 | 20.16 |
| Earnings Per Share, Diluted | -78.8% | 1.21 | 1.99 | 3.13 | 4.93 | 13.47 | 20.16 |
| Debt equity ratio | - | - | - | - | - | 0 | - |
| Debt service coverage ratio | - | - | - | - | - | 0 | - |
| Interest service coverage ratio | - | - | - | - | - | 0 | - |
| -100.7% |
| 0 |
| 137 |
| 137 |
| 137 |
| 137 |
| 137 |
| Non-current investments | 31.1% | 2,172 | 1,657 | 1,657 | 1,657 | 1,657 | 1,657 |
| Loans, non-current | -25% | 0 | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 |
| Total non-current financial assets | 30.7% | 2,180 | 1,668 | 1,669 | 1,668 | 1,668 | 1,666 |
| Total non-current assets | -4.3% | 2,321 | 2,425 | 2,441 | 2,451 | 2,449 | 2,430 |
| Total assets | -18.4% | 2,376 | 2,910 | 2,892 | 2,992 | 3,014 | 3,008 |
| Borrowings, non-current | -78.9% | 50 | 233 | 244 | 246 | 250 | 174 |
| Total non-current financial liabilities | -80.2% | 51 | 254 | 267 | 247 | 282 | 209 |
| Provisions, non-current | -68.5% | 9.5 | 28 | 27 | 27 | 24 | 23 |
| Total non-current liabilities | -76.8% | 66 | 281 | 295 | 302 | 306 | 233 |
| Borrowings, current | -101.4% | 0 | 73 | 78 | 96 | 123 | 128 |
| Total current financial liabilities | -86.9% | 36 | 268 | 249 | 282 | 327 | 330 |
| Provisions, current | -52.1% | 4.5 | 8.3 | 6.8 | 6.9 | 10 | 11 |
| Current tax liabilities | 0% | 13 | 13 | 0.2 | 0.2 | 0.2 | 0.16 |
| Total current liabilities | -79.3% | 65 | 310 | 298 | 315 | 368 | 361 |
| Total liabilities | -77.8% | 132 | 592 | 593 | 617 | 674 | 594 |
| Equity share capital | 0% | 16 | 16 | 16 | 16 | 16 | 16 |
| Total equity | -3.2% | 2,244 | 2,318 | 2,299 | 2,374 | 2,340 | 2,415 |
| Total equity and liabilities | -18.4% | 2,376 | 2,910 | 2,892 | 2,992 | 3,014 | 3,008 |
| -3.9% |
| 148 |
| 154 |
| -47.67 |
| 13 |
| - |
| - |
| Income taxes paid (refund) | 0% | 12 | 12 | 17 | 19 | - | - |
| Other inflows (outflows) of cash | - | 0 | 1 | 0 | 0 | - | - |
| Net Cashflows From Operating Activities | -4.9% | 136 | 143 | -65.12 | -6.47 | - | - |
| Cashflows used in obtaining control of subsidiaries | - | 0 | 0 | 8.75 | 0 | - | - |
| Proceeds from sales of PPE | - | 0 | 0 | 0.92 | 0.04 | - | - |
| Purchase of property, plant and equipment | -70.1% | 21 | 68 | 60 | 1.95 | - | - |
| Proceeds from sales of investment property | -500% | 0.4 | 0.9 | 0 | 0 | - | - |
| Cash receipts from repayment of advances and loans made to other parties | - | 0 | 0 | 0.05 | 0 | - | - |
| Dividends received | -43.8% | 19 | 33 | 97 | 97 | - | - |
| Interest received | 157.1% | 1.4 | 0.3 | 0.58 | 0.87 | - | - |
| Other inflows (outflows) of cash | -18.2% | -0.3 | -0.1 | -0.12 | 0 | - | - |
| Net Cashflows From Investing Activities | 92% | -2.3 | -40.3 | 31 | 96 | - | - |
| Proceeds from borrowings | -101% | 0 | 100 | 128 | 6 | - | - |
| Repayments of borrowings | 9.1% | 37 | 34 | 0 | 0 | - | - |
| Payments of lease liabilities | 7.1% | 10 | 9.4 | 6.76 | 2.93 | - | - |
| Dividends paid | 0% | 80 | 80 | 80 | 80 | - | - |
| Interest paid | 0% | 30 | 30 | 18 | 30 | - | - |
| Other inflows (outflows) of cash | 96.2% | 0 | -25 | 0 | 0 | - | - |
| Net Cashflows from Financing Activities | -100.3% | -156.8 | -77.8 | 23 | -107.37 | - | - |
| Net change in cash and cash eq. | -202.1% | -23.5 | 25 | -11.54 | -17.82 | - | - |
Analysis of JUBILANT PHARMOVA's financial performance, highlighting revenue trends, growth patterns, and key metrics through quarterly analysis.
Last Updated: Dec 31, 2025
| Description | Share | Value |
|---|---|---|
| Radiopharma | 43.7% | 934.4 Cr |
| Contract Development and Manufacturing Organisation - Sterile Injectables | 21.6% | 462 Cr |
| Contract Research, Development and Manufacturing Organisation | 14.3% | 306.2 Cr |
| Generics | 10.6% | 226.1 Cr |
| Allergy Immunotherapy | 9.0% | 192.7 Cr |
| Unallocable corporate | 0.7% | 14.9 Cr |
| Total | 2.1 kCr |